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Summary
The term ‘neurasthenia ’  is  ra ther  confusing,
par t icu lar ly  fo r  the  Chinese.   I t  has  undergone
metamorphosis, and is nowadays characterised by
unexplained persistent physical symptoms especially
chronic fatigue.  It is a common presentation to primary
care doctors, and these patients are frequent consumers
of health care services of various types.  There is a high
associat ion with psychological distress and other
psychiatric disorders have to be ruled out in order to
reduce confusion.  Treatment is rather non-specific,
though antidepressants and/or cognitive-behavioural
therapy can be quite effective.  The author recommends
that the term ‘eurasthenia’ be used as a layman term while
communicating with the patient, but to use ‘chronic
fatigue syndrome’ as a medical terminology when
corresponding with other colleagues.
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Introduction and history
The term ‘neurasthenia’ has meant different things
in different places to different people.  Literally, the word
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means ‘nerves exhaustion’, thus conveying some physical
problems with the body.
Brown, a pupil of Cullen, developed the concept of
neurasthenia at the end of the 18th century to describe
general functional disorders of the nervous system with
no specific localised lesions found.  Kraus in 1831 and
Most in 1836 equated neurasthenia as a synonym for
nervous weakness, and von Deusen wrote about the topic
some 30 years later.1  However, it was George M Beard
who in 1867 described more than 50 symptoms, both
phys ica l  and  menta l ,  tha t  can  be  d iagnosed  as
neurasthenia.  The main feature is that of unexplained
chronic ‘fatigue’ and weakness.2  According to him, the
disorder was the exhaustion of the nervous force caused
by environmental factors and rapid social changes in
society such as the telegraph, the railroads, political and
religious liberty, etc.
In France, Charcot reclassified the symptoms and
expanded the concept further to become the second ‘great
neuroses’ besides hysteria.  Gradually, this concept
declined in popularity because its symptomatology was
too vast and protean, and the hypothesis of ‘nervous
weakness’ was unverifiable.  It was replaced by the new
psychopathological concept of anxiety (developed by
Freud who associated it with sexuality and Janet who
replaced it with the term ‘psychasthenia’  to mean
psychological tension) and also depression (expounded by
Kraepelin into psychogenic depression).
The concept of neurasthenia was however maintained
in Russia, with Pavlov dividing neuroses into hysteria and
neurasthenia, with the latter further subdivided into the
hypersthenic form (irritable) and hyposthenic form
(depression).  In Japan, Morita published his work on
neurasthenia (or ‘shinkeishitu’) and it was regarded as a
‘culture-specific’ syndrome, he even proposed a specific
psychotherapy still in use today.3  As many doctors in
China were trained in the USSR after the communist
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takeover, the term ‘neurasthenia’ (or ‘shen-jin-shui-rue’)
remained a popular diagnosis in China for the past few
decades.  Arthur Kleinman4 studied a population of
patients thus diagnosed in China, and found that many
were actually suffering from ‘anxiety disorder’ and/or
‘depressive disorder’.  In a way, the Chinese patients
(especially the elderly) are more willing to accept medical
treatment for the label of ‘neurasthenia’, compared to the
more specific diagnosis of ‘depressive disorder’, ‘anxiety
disorder’ or ‘somatisation disorder’.  In order to avoid
confusion and to improve compliance in treatment, the
present author recommends that clinicians could perhaps
still maintain the layman term ‘neurasthenia’ when giving
a diagnosis acceptable to their patients.  However, they
should perhaps use the term ‘chronic fatigue syndrome’
when discussing the disorder in a professional manner.
In a way, the sense of organicity felt by many
patients suffering from the disorder does merit some
consideration.  It has been known for a long time that
fatigue often occurs after an infection, either a viral or a
bacteria infection.  Infectious mononucleosis and
brucellosis are famous examples.  In recent years, chronic
fatigue syndrome has been associated with the so-called
ME syndrome (myalgic encephalomyelitis, also called
‘post-viral fatigue’).  In a way, ME implies an infection
involving the neurological system, and viruses such as the
Coxsackie B, the human herpes virus and the Epstein-Barr
virus have been implicated.  However, evidence of
previous infection by the above viruses are commonly
found even in normal persons.  This has already given to
some confusion in the diagnosis of chronic fatigue
syndrome.
Ayres et al 5 found exposure to Coxiella burnetii
(Q fever) is related to the later manifestation of chronic
fatigue.  Using magnetic resonance imaging on patients
with severe post-poliomyelitis fatigue, Bruno et al6 found
small discrete punctuate areas of hyperintense signal in
the reticular formation, putamen, medial lemniscus and
white matter tracts.  Together with the Positron Emission
Tomography (PET) and Single  Photon Emission
Computed Tomography (SPECT) findings of reduced
cortical blood flow in the brain stem,7 Dickinson8
hypothesized that chronic fatigue syndrome is secondary
to damages of the ascending reticular activating system
at the brain stem.  Nevertheless, in many other fatigue
patients, no physical or laboratory abnormalities are
found.   Other  biological  causes  such as  muscle
dysfunction (including myofibrils abnormalities), brain
pathologies and immunoglobulin deficiencies have also
been proposed; but again definitive laboratory findings are
still lacking.9
Prevalence
Fatigue is a common presenting symptom to primary
care doctors, and about three-quarters of the patients
experience persistent fatigue.10  Kroenke et al11 found that
about a quarter of the adult patients attending primary
care clinics complainted of chronic fatigue and weakness.
Hall et al 12 found a highly significant increase in illness
reporting before developing the chronic fatigue syndrome.
The group’s recent study found a more frequent
consultation illness behaviour (for a variety of problems)
for 15 years even before developing the syndrome,
compared to the control groups.13
The risk of chronicity increases when there is
concurrent psychological distress, either in the past or in
the present.10  According to papers published,14,15 as many
as 60-80% of all psychiatric outpatients in China are
diagnosed as suffering from this disorder.
The diagnosis is less common in children and
adolescents.16  In Switzerland, the one-year prevalent rate
was estimated to be 5% for men and 10% for women.  It
was also found that no less than 79% of diagnosed
patients had concurrent or successive diagnoses of
depression or anxiety disorder.17  Hagnell18 in his 25-year
study, found that the frequency of fatigue was higher in
women than in men during the period 1947-1956, but the
frequency among men increased and became equal during
1957-1972.
Clinical features
Because of the confusion in diagnosis, different
authorities have different clusters of symptoms for
neurasthenia, and the diagnostic features have changed
over the years.  For example, Beard19 divided his 50
symptoms in to  ‘mental  symptoms ’  e .g .  psychic
fatiguability, inability to concentrate, etc. and ‘bodily or
physical exhaustion’ e.g. pains, muscular tension, etc.  He
even divided the symptoms into eight different groups.
Using cluster analysis, the Zurich group17 regrouped the
symptoms into three clusters:
(Continued on page 393)
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1. hypersensitivity, nervousness, and reduced stress
tolerance;
2. poor concentration and memory deficits;
3. tiredness and increased sleep requirements.
Var ious a t tempts  had been made to  class i fy
neurasthenia.  Because of its widespread use and the
continuing existence of syndromes that do not seem to be
assignable to any of the other conditions,20 the term
‘neurasthenia’  remains in the ICD-10.  But in the
DSM-IV classification,  there is  no such specific
diagnosis, unexplained physical symptoms such as fatigue
or body weakness of less than 6 months’ duration that are
not due to another mental disorder is classified under the
category of  ‘somatoform disorder  not  otherwise
specified’.
But  according to  the ICD-10,  there  are  two
conditions, either
1. persistent and distressing complaints of feelings of
exhaustion after minor mental effort (such as
performing or attempting to perform everyday tasks
that do not require unusual mental effort); or
2. persistent and distressing complaints of feelings of
fatigue and bodily weakness after minor physical
effort.
At least one of the following symptoms must be
present in order to diagnose neurasthenia: feelings of
muscular aches and pains, dizziness, tension headaches,
sleep disturbance, inability to relax and irritability.  Note
that these symptoms are very common and non-specific
(they can occur in many other psychiatric disorders), and
are thus of not much diagnostic value.  One condition for
the diagnosis is that the patient is unable to recover by
means of rest, relaxation or entertainment.
As mentioned above, the diagnosis made by Chinese
doctors is quite non-specific and often is a mixture of
somatic, anxiety and depressive symptoms.4  So far, there
is no published scientific report known to the author as
regard the presenting features of Chinese patients
suffering from the pure ‘chronic fatigue syndrome’.
Differential diagnosis (and/or comorbidity)
From the above discussion it is obvious that the
cardinal symptoms of neurasthenia are frequently seen in
patients with other clinical diagnoses, especially:
1. Anxiety and/or depressive disorders including
dysthymia,
2. Stress related disorders including adjustment
disorder, and
3. Somatoform disorder, particularly fibromyalgia.
In a survey in Shanghai, China by Zhang,21 the most
frequent comorbid diagnosis in neurasthenic patients
using the Diagnostic Interview Schedule was depression
(67.5%), generalised anxiety disorder (50%) and
somatoform disorder (62.5%).  Each patient has an
average of 2.6 syndromes.  Whether these should be
considered as comorbidities or whether they should
replace  ‘neuras thenia ’  a l together  i s  s t i l l  ra ther
controversial.
Quite often, neurasthenia is associated with the
premenstrual  syndrome and the post-menopausal
syndrome, but further studies are needed to establish the
link.  Shift work that would disturb the sleep/wake cycle
is also a precipitator, and sleep apnoea can induce
daytime sleepiness.  It should be noted that certain
medications (especially tranquillizers and antihistamines),
opioids and alcohol, and even certain environmental
toxins can cause neurasthenia-like symptoms.  Withdrawal
from stimulants and narcotic intoxication can also induce
severe fatigue.
Management
Assessment
Concerning chronic fatigue in particular, the Fatigue
Questionnaire22 and the Fatigue Severity Scale23 can be
quite helpful.  It is useful to exclude Somatisation
Disorders, Anxiety Disorders or Depressive Disorders
clinically, and Stress Related Disorders should also be
ruled out.  Physical causes including medications and
substance abuse have to be ruled out (Table 1).
For patients presenting with a prolonged and
incapacitating state of fatigue, a complete physical
examination and laboratory investigations are necessary
to rule out genuine organic disorders.  If there was a
previous episode of acute infection, it is justified to do
the following tests:
• a complete blood picture, electrolytes including Na+,
K+, Ca+, Mg+, blood glucose test, liver and renal
function tests, plasma cortisol level;
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• a tuberculin test;
• serological tests for HIV, CMV, hepatitis A, B & C;
• blood androgen level for men aged over 50;
• any other tests according to clinical indications.
Treatment
In the earliest days, Beard24 recommended aggressive
medical and electrical treatment for neurasthenia.  It was
the American neurologist Silas Weir Mitchell who in 1871
proposed the ‘rest cure’.  In Japan, the Morita therapy
requiring prolonged bed-rest was designed to treat such
a condition.3  However, this measure (if successful) is an
exclusion criterion in the ICD-10 diagnosis.  Nevertheless,
a healthy lifestyle with a balanced diet (especially in the
elderly), initial rest followed by gradual increase in
exercise capacity, and a graded resumption of everyday
recreation are often recommended.
Despite a lack of understanding of aetiology, chronic
fatigue syndrome can still be treated.  Time and attention
paid to the patients are sometimes therapeutic, relaxation
techniques can be taught.  Any underlying or coexisting
physical disease or psychiatric disorder should be treated
accordingly.  Some antidepressants, especially bupropion
and reboxetine which have some stimulating properties,
have been tried with varying success.  Salbutamine, a
specific cholinergic agent (acting on the muscarinic
receptors of the nervous system) has been found useful
in hastening recovery of patients with post-infection
fatigue.25  Psycho-stimulants such as methylphenidate and
other amphetamine derivatives, have been tried but there
is the adverse problem of substance abuse.  Modafinal, a
newer type of stimulant which acts on the dopamine and
noradrenaline systems, has recently been used with some
success.
On the psychotherapy side, cognitive-behavioural
therapy (CBT) for the chronic fatigue syndrome appears
more  e ffec t ive  than  the  usua l  medica l  ca re  o r
relaxation,26,27 CBT consisted of ‘a treatment rationale,
activity planning, homework, establishing a sleep routine
and other cognitive interventions’.  The counseling skills
in this study consisted of a non-directive and client-
centred approach, allowing the patients to talk through
their  concerns  and difficul t ies ,  wi th  the  a im to
‘understand themselves better, to suggest alternative
understandings, to uncover the links between current
distress and past experience, and to provide the conditions
for growth and healing’.
Other treatment strategies have been developed
according to the viewpoints whether it is organic (like the
ME syndrome) or psychogenic.  For the latter, treatment
varies according to its inclusiveness or exclusiveness of
other ‘minor psychiatric disorders’.  In a way, it is not
easy to refer such patients to a psychiatrist as many would
regard the disorder as organic in origin.  Sometimes,
referral is possible only after the patients have exhausted
the list of non-psychiatrist physicians and have undergone
extensive investigations to no avail.
Prognosis
For treated patients, the probability of relapse is quite
high.17  As mentioned, fatigue syndromes if untreated will
run a chronic course, and can be quite costly to the health
care providers.  In Australia, the overall economic cost
for chronic fatigue syndrome was estimated to be
Australian $9429 per patient due mainly to the loss of
employment.28  In fact, such chronic disorder is highly
correlated to unemployment and consumption of various
types of health services.29
Conditions Examples
Sleep disorders sleep apnoea, insomnia, etc.
Cardiovascular diseases congestive heart failure, sub-
acute endocarditis, etc.
Pulmonary diseases chronic obstructive lung disease,
pleural effusion, etc.
Infectious diseases HIV, cytomegalovirus, etc.
Neoplastic diseases l y m p h o m a  a n d  o t h e r
malignancies, etc.
Neurologic diseases multiple sclerosis, myositis, etc.
Endocrine diseases hypothyroidism, hypogonadism,
etc.
Gastrointestinal diseases hepatitis, pancreatitis, etc.
Miscellaneous medical diseases c h r o n i c  a l l e rg i c  r h i n i t i s ,
anaemia, etc.
Treatment induced chemotherapy, surgery, radio-
therapy, etc.
Table 1: Medical conditions presenting with fatigue
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Key messages
1. Neurasthenia or ‘shen-jin-shui-rue’ is a confusing
t e r m ,  a n d  s h o u l d  b e  avo i d e d  i n  s c i e n t i f i c
communication until further refined.
2. The term is acceptable to patients, especially to the
older generation Chinese, and this may help to
improve the compliance to treatment.
3. The term ‘chronic fatigue syndrome’ is a more
appropriate medical description, but should merit
detailed physical and psychological examinations
to rule out primary causes.
4. Such chronic syndrome is not uncommon in primary
care, and family practitioners are in a good position
to manage such a condition.
5. Though ‘chronic fatigue syndrome’ is difficult to
cure, both medications and psychotherapies are
worth trying.
Conclusion
In a way, ‘neurasthenia’ is perhaps the name given
to a set of symptoms that are non-specific reactions to
subacute irr itation of the central nervous system.
According to Sartorius20 who called it a ‘disease of
modernisation’ ,  there are st i l l  a few unanswered
questions:
i. Is there a difference between fatigability and fatigue?
ii. Do fatigue, asthenia and exhaustion constitute a
dimension of human existence, differing from one
individual to another but being present in all of us,
or perhaps a categorical problem?
iii. What is the significance of the social-class and sex
differences in the appearance of the syndromes and
of their change over the years?
iv. Should treatment strategies employed be the same
regardless of whether the condition appears on its
own or as a part of another disorder?
Nobody knows whether this term ‘neurasthenia’ may
one day, like ‘hysteria’, disappear from the clinical
diagnosis in psychiatry.  On the other hand, some would
like to revive this term for some specific syndromes.
Meanwhile, in order to avoid confusion, it is better to
follow the trend of replacing ‘neurasthenia’ by a more
specific term such as ‘chronic fatigue syndrome or
disorder’.   
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